亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Metformin in Combination With Chemoradiotherapy in Locally Advanced Non–Small Cell Lung Cancer

医学 不良事件通用术语标准 放化疗 内科学 肺癌 肿瘤科 二甲双胍 不利影响 中止 放射治疗 外科 化疗 胰岛素
作者
Theodoros K. Tsakiridis,Gregory R. Pond,Jim Wright,Peter M. Ellis,Naseer Ahmed,Bassam Abdulkarim,Wilson Roa,Andrew George Robinson,Anand Swaminath,Gordon S. Okawara,Marcin Wierzbicki,Mario Valdes,Mark N. Levine
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:7 (9): 1333-1333 被引量:112
标识
DOI:10.1001/jamaoncol.2021.2328
摘要

IMPORTANCE: Unresected locally advanced non-small cell lung cancer (LA-NSCLC) shows poor survival outcomes even after aggressive concurrent chemoradiotherapy. Whether metformin, a diabetes agent that inhibits the mitochondria oxidative phosphorylation chain, could improve radiotherapy and chemotherapy response in LA-NSCLC remains to be studied. OBJECTIVE: To examine whether metformin, given concurrently with chemoradiotherapy and as consolidation treatment, could improve outcomes in patients with LA-NSCLC. DESIGN, SETTING, AND PARTICIPANTS: The Ontario Clinical Oncology Group Advanced Lung Cancer Treatment With Metformin and Chemoradiotherapy (OCOG-ALMERA) study was a multicenter phase 2 randomized clinical trial. Patients were stratified for stage IIIA vs IIIB LA-NSCLC and use of consolidation chemotherapy. The trial was designed to enroll 96 patients with unresected LA-NSCLC who did not have diabetes. The trial was conducted from September 24, 2014, to March 8, 2019. INTERVENTIONS: Patients were randomized to platinum-based chemotherapy, concurrent with chest radiotherapy (60-63 Gy), with or without consolidation chemotherapy or the same treatment plus metformin, 2000 mg/d, during chemoradiotherapy and afterward for up to 12 months. MAIN OUTCOMES AND MEASURES: The primary outcome was the proportion of patients who experienced a failure event (ie, locoregional disease progression, distant metastases, death, and discontinuation of trial treatment or planned evaluations for any reason within 12 months). Proportions were compared using a 2-sided Fisher exact test. Conventional progression-free and overall survival were estimated using the Kaplan-Meier method. Adverse events were graded with Common Terminology Criteria for Adverse Events, version 4.03. All randomized patients were included in an intention-to-treat analysis. RESULTS: The trial was stopped early due to slow accrual. Between 2014 and 2019, 54 patients were randomized (26 in experimental arm and 28 in control arm). Participants included 30 women (55.6%); mean (SD) age was 65.6 (7.6) years. Treatment failure was detected in 18 patients (69.2%) receiving metformin within 1 year vs 12 (42.9%) control patients (P = .05). The 1-year progression-free survival rate was 34.8% (95% CI, 16.6%-53.7%) in the metformin arm and 63.0% (95% CI, 42.1%-78.1%) in the control arm (hazard ratio, 2.42; 95% CI, 1.14-5.10) The overall survival rates were 47.4% (95% CI, 26.3%-65.9%) in the metformin arm and 85.2% (95% CI, 65.2%-94.2%) in the control arm (hazard ratio, 3.80; 95% CI, 1.49-9.73). More patients in the experimental arm vs control arm (53.8% vs 25.0%) reported at least 1 grade 3 or higher adverse event. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, the addition of metformin to chemoradiotherapy was associated with worse treatment efficacy and increased toxic effects compared with combined modality therapy alone. Metformin is not recommended in patients with LA-NSCLC who are candidates for chemoradiotherapy. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02115464.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
康子浩发布了新的文献求助10
2秒前
贪玩的夏真完成签到,获得积分10
3秒前
雨落瑾年完成签到,获得积分0
13秒前
lin完成签到,获得积分10
13秒前
Glufo完成签到,获得积分10
15秒前
俏皮的灵完成签到,获得积分10
15秒前
17秒前
臭学医的完成签到 ,获得积分10
18秒前
大溺完成签到 ,获得积分10
21秒前
传奇3的应助被DRJ采纳,获得10
25秒前
思源的应助被雪山大地采纳,获得10
25秒前
27秒前
Aixx完成签到 ,获得积分10
31秒前
可靠友梅完成签到,获得积分10
32秒前
YU完成签到,获得积分10
36秒前
Leowo完成签到,获得积分10
36秒前
和谐以冬完成签到,获得积分10
38秒前
40秒前
深情安青的应助被Qiaoguliang采纳,获得10
41秒前
41秒前
Moooi完成签到,获得积分10
44秒前
45秒前
莫里亚蒂完成签到,获得积分10
48秒前
Charlie完成签到 ,获得积分10
49秒前
Yu完成签到 ,获得积分10
50秒前
可爱的函函的应助被DRJ采纳,获得10
51秒前
52秒前
55秒前
56秒前
莫里亚蒂完成签到,获得积分10
57秒前
57秒前
Ch发布了新的文献求助10
59秒前
NexusExplorer的应助被wstki采纳,获得10
59秒前
哈哈哈哈发布了新的文献求助10
1分钟前
1分钟前
1分钟前
高分子聚合绿豆汤完成签到 ,获得积分10
1分钟前
勤奋柜子的应助被雪山大地采纳,获得10
1分钟前
Ahloe发布了新的文献求助10
1分钟前
JohnYoung发布了新的文献求助10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8165776
求助须知:如何正确求助?哪些是违规求助? 9559273
关于积分的说明 21749731
捐赠科研通 7756580
什么是DOI,文献DOI怎么找? 3429034
关于科研通互助平台的介绍 2553319
邀请新用户注册赠送积分活动 2473606